New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
09:22 EDTSTJ, MDT, HTWR, ABT, EW, COVCovidian acquisiton may signal increased sector M&A, says CRT Capital
CRT Capital believes Medtronic's (MDT) acquisition of Covidien (COV) may signal an increase in sector M&A. The analyst believes potential combinations that make strategic sense are Abbott (ABT) or St. Jude Medical (STJ) for Edwards Lifesciences (EW) or a takeover of HeartWare (HTWR).
News For MDT;COV;ABT;STJ;EW;HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 2, 2015
12:54 EDTMDTNuVasive gets mixed appeals court ruling in patent fight with Medtronic
Subscribe for More Information
12:13 EDTSTJOn The Fly: Midday Wrap
Subscribe for More Information
11:34 EDTSTJSt. Jude Medical shares up after ACC abstract, says Wells Fargo
Subscribe for More Information
08:55 EDTEW, MDTEdwards Lifesciences Medtronic likely to get positive catalyst, says Wells Fargo
Subscribe for More Information
February 27, 2015
12:35 EDTABTMylan completes acquisition of assets from Abbott
Mylan N.V. and Mylan (MYL) announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Under the previously announced terms of the transaction agreement, Abbott received 110M shares of Mylan N.V., resulting in former Mylan shareholders now owning approximately 78% of Mylan N.V. and Abbott now owning approximately 22% of Mylan N.V. Mylan Inc. and Abbott's non-U.S. developed markets specialty and branded generics business have been reorganized under Mylan N.V., a new public company organized in the Netherlands. Mylan N.V. will be led by the former Mylan Inc. executive team. The company will trade on Nasdaq under the ticker symbol MYL.
09:02 EDTMDTMedtronic announces Irish High Court approval of share premium reduction
Subscribe for More Information
07:40 EDTHTWRHeartWare price target raised to $105 from $90 at Leerink
Subscribe for More Information
February 26, 2015
12:43 EDTSTJSt. Jude Medical management to meet with Piper Jaffray
Subscribe for More Information
07:03 EDTHTWRHeartWare reports 737 HeartWave Ventricular Assist Systems sold globally
U.S. revenue, generated through the sale of 382 units during the fourth quarter of 2014, was $41.5 million, a 60% increase from $25.9 million in the fourth quarter of 2013.
07:02 EDTHTWRHeartWare reports Q4 non-GAAP EPS (41c), consensus (59c)
Subscribe for More Information
February 24, 2015
13:02 EDTMDTMedtronic confirms FDA approval of VenaSeal closure system
Subscribe for More Information
10:00 EDTSTJOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AMC Networks (AMCX) downgraded to Neutral from Outperform at Macquarie... American Airlines (AAL) downgraded to Market Perform at Cowen... Armstrong World (AWI) downgraded to Hold from Buy at KeyBanc... Basic Energy (BAS) downgraded to Outperform from Strong Buy at Raymond James... CSC (CSC) downgraded at Stifel... Chevron (CVX) downgraded to Perform from Outperform at Oppenheimer... Choice Hotels (CHH) downgraded to Underweight from Equal Weight at Barclays... Eni SpA (E) downgraded to Underperform from Hold at Jefferies... Fifth Street Asset (FSAM) downgraded to Neutral from Outperform at Credit Suisse... HSBC (HSBC) downgraded to Neutral from Buy at UBS... Home Loan Servicing (HLSS) downgraded to Neutral from Overweight at Piper Jaffray... Huntington Ingalls (HII) downgraded to Underperform from Neutral at Credit Suisse... International Paper (IP) downgraded to Hold from Buy at Deutsche Bank... Kayne Anderson (KED) downgraded at Stifel... Landstar System (LSTR) downgraded to Hold from Buy at Deutsche Bank... Multi-Color (LABL) downgraded to Neutral from Long-Term Buy at Hilliard Lyons... Newmont Mining (NEM) downgraded to Neutral from Overweight at HSBC... ONEOK Partners (OKS) downgraded to Underweight from Neutral at JPMorgan... ONEOK (OKE) downgraded to Underweight from Neutral at JPMorgan... Olympic Steel (ZEUS) downgraded to Underperform from Neutral at Credit Suisse... Polypore (PPO) downgraded to Market Perform from Outperform at William Blair... Rosetta Resources (ROSE) downgraded to Equal Weight from Overweight at Stephens... Salix (SLXP) downgraded to Neutral from Buy at UBS... Sprint (S) downgraded to Sell from Neutral at BTIG... St. Jude Medical (STJ) downgraded to Underperform from Outperform at Credit Suisse... Timmins Gold (TGD) downgraded on lack of near-term production catalysts at RBC Capital... Transocean Partners (RIGP) downgraded to Underweight from Equal Weight at Barclays... Vodafone (VOD) downgraded to Underperform from Neutral at BofA/Merrill... Williams Partners (WPZ) downgraded to Neutral from Buy at Citigroup... Williams (WMB) downgraded to Neutral from Buy at Citigroup... Worthington (WOR) downgraded to Neutral from Outperform at Credit Suisse... Zillow Group (Z) downgraded at Macquarie.
07:14 EDTSTJSt. Jude Medical downgraded to Underperform from Outperform at Credit Suisse
Credit Suisse downgraded St. Jude Medical two notches to Underperform based on expectations the Cardiac Rhythm Management segment and shares will under perform peers given competition from Medtronic's (MDT) Quadriplar ICD U.S. launch, Boston Scientific's (BSX) next-gen launch of its subcutaneious ICD, MRI-safe ICD competition in Japan, and the delay in the return of St. Jude's Nanostim to the European market. Price target is $74.
February 23, 2015
08:40 EDTMDTMedtronic acquires Advanced Uro-Solutions, terms not disclosed
Medtronic announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.
07:28 EDTHTWRHeartWare recall should not have material impact long-term, says Canaccord
Canaccord does not believe the voluntary recall issued by HeartWare should not have any material impact on its business long-term, as the serious event rate is relatively low. The recall pertains to a previously known issue and is in effect a continuation of its 2013 corrective action, Canaccord said. The firm reiterated its Buy rating and $115 price target on HeartWare shares.
February 20, 2015
16:35 EDTHTWRHeartWare issues recall of older HeartWare clinical trial controllers
Subscribe for More Information
14:43 EDTSTJSt. Jude Medical raises quarterly dividend 7%
Subscribe for More Information
12:19 EDTMDTFDA approves closure system to permanently treat varicose veins
Subscribe for More Information
07:08 EDTABTAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
16:15 EDTMDTMedtronic SANTE trial data show sustained safety, improvements in QOLIE-31
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use